Suppr超能文献

[用于全身麻醉及院内和院外镇痛的新型阿片类药物]

[New opioids for general anaesthesia and in- and out-hospital analgesia].

作者信息

Dabrowska-Wójciak Iwona, Piotrowski Andrzej

机构信息

Kliniczny Oddział Anestezjologii i Intensywnej Terapii UM w Łodzi.

出版信息

Anestezjol Intens Ter. 2008 Jan-Mar;40(1):39-43.

Abstract

Over the last 30 years, three new opioids of the piperidine family have been introduced to anaesthesia clinical practice: sufentanil, alfentanil and remifentanil. Alfentanil is a derivative of fentanyl, with quicker onset than that of fentanyl and with shorter duration and more intense vagomimetic properties than those of fentanyl and sufentanil. It may cause less intense respiratory depression than equianalgesic doses of fentanyl. Clinical trials indicate that alfentanil can be used effectively as an analgesic, as an analgesic supplement to anaesthesia, and as the major component of a general anaesthetic. Its short duration of effect makes it attractive as an analgesic supplement for short ambulatory surgical procedures. Sufentanil is a more potent and more lipophilic analgesic than fentanyl. It would appear to maintain haemodynamic stability during surgery better than other opioids. Epidural sufentanil produces a rapid onset and good quality of analgesia. In addition, low doses administered intravenously via a PCA pump seem to have a potential role for analgesia during labour. Remifentanil is an opioid analgesic that is rapidly metabolized by non-specific blood and tissue esterases. According to its unique pharmacokinetic profile, remifentanil-based anaesthesia combines high-dosage opioid analgesia intraoperatively with a rapid and predictable postoperative awakening, even after long procedures. Its vagomimetic properties are especially pronounced in small children, the elderly and hypovolaemic patients, and in these groups atropine should be always given before remifentanil administration. Remifentanil also minimises the adrenergic response to endotracheal intubation. Three mju agonist-antagonists have been used for pain treatment: nalbuphine, butorphanol and buprenorphine. They can be used in ambulatory settings. Nalbuphine can be used parenterally. It reverses morphine-induced respiratory depression while maintaining adequate analgesic effect. Buprenorphine can be given sublingually, percutanenously, epidurally and parenterally. It is a potent analgesic, recommended for strong postoperative pain. Butorphanol is a potent analgesic that increases heart rate, arterial and pulmonary blood pressures and cardiac output. It should be given carefully in patients with coronary disease.

摘要

在过去30年里,哌啶家族有三种新型阿片类药物被引入麻醉临床实践:舒芬太尼、阿芬太尼和瑞芬太尼。阿芬太尼是芬太尼的衍生物,起效比芬太尼快,作用持续时间比芬太尼和舒芬太尼短,拟迷走神经作用更强。与等效镇痛剂量的芬太尼相比,它引起的呼吸抑制可能较轻。临床试验表明,阿芬太尼可有效用作镇痛药、麻醉的镇痛补充剂以及全身麻醉的主要成分。其作用持续时间短,使其成为短小门诊手术镇痛补充剂的理想选择。舒芬太尼是一种比芬太尼更强效、亲脂性更高的镇痛药。在手术过程中,它似乎比其他阿片类药物能更好地维持血流动力学稳定。硬膜外注射舒芬太尼起效迅速,镇痛效果良好。此外,通过PCA泵静脉注射低剂量舒芬太尼似乎在分娩镇痛中具有潜在作用。瑞芬太尼是一种阿片类镇痛药,可被非特异性血液和组织酯酶快速代谢。根据其独特的药代动力学特征,基于瑞芬太尼的麻醉在术中结合了高剂量阿片类镇痛与快速且可预测的术后苏醒,即使是长时间手术之后。其拟迷走神经特性在小儿、老年人和低血容量患者中尤为明显,在这些人群中,应在给予瑞芬太尼之前始终给予阿托品。瑞芬太尼还可将气管插管的肾上腺素能反应降至最低。三种μ激动剂 - 拮抗剂已用于疼痛治疗:纳布啡、布托啡诺和丁丙诺啡。它们可用于门诊环境。纳布啡可胃肠外给药。它可逆转吗啡引起的呼吸抑制,同时维持足够的镇痛效果。丁丙诺啡可舌下、经皮、硬膜外和胃肠外给药。它是一种强效镇痛药,推荐用于术后剧痛。布托啡诺是一种强效镇痛药,可增加心率、动脉压和肺动脉压以及心输出量。冠心病患者应谨慎使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验